Patents by Inventor Mart Ustav, Sr.

Mart Ustav, Sr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230340542
    Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.
    Type: Application
    Filed: May 10, 2023
    Publication date: October 26, 2023
    Inventors: Kadri ÕUNAP, Eva-Maria TOMBAK, Mart TOOTS, Madis JAKOBSON, Mart USTAV, Jr., Kerttu MURUMETS, Urve TOOTS, Andres MÄNNIK, Mart USTAV, Sr.
  • Patent number: 11685936
    Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: June 27, 2023
    Assignee: Icosagen Cell Factory OÜ
    Inventors: Kadri Õunap, Eva-Maria Tombak, Mart Toots, Madis Jakobson, Mart Ustav, Jr., Kerttu Murumets, Urve Toots, Andres Männik, Mart Ustav, Sr.
  • Patent number: 11000529
    Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: May 11, 2021
    Assignee: Icosagen Cell Factory OÜ
    Inventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
  • Publication number: 20200123576
    Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.
    Type: Application
    Filed: October 17, 2019
    Publication date: April 23, 2020
    Applicant: Icosagen Cell Factory OÜ
    Inventors: Kadri ÕUNAP, Eva-Maria TOMBAK, Mart TOOTS, Madis JAKOBSON, Mart USTAV, Jr., Kerttu MURUMETS, Urve TOOTS, Andres MÄNNIK, Mart USTAV, Sr.
  • Publication number: 20200046730
    Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 13, 2020
    Applicant: Icosagen Cell Factory OÜ
    Inventors: Mart USTAV, SR., Ene USTAV, Andres MÄNNIK, Mart TOOTS, Andres TOVER
  • Patent number: 10543218
    Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Icosagen Cell Factory OÜ
    Inventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
  • Publication number: 20180133228
    Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Application
    Filed: May 11, 2016
    Publication date: May 17, 2018
    Applicant: Icosagen Cell Factory OÜ
    Inventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover